Venous thromboembolism (VTE) and cancer are two major public health issues that are closely linked. Cancer is part of the major risk factors for VTE and it is estimated that up to 20% of cancer patients will face a VTE issue during the course of their malignancy [1,2]. Patients who develop VTE during the course of their malignancy are at high risk for VTE recurrence: 10 to 17% of them will experience a new VTE event within the first six months of anticoagulation [3]. However, this risk varies depending on several parameters such as cancer site, cancer histology, or cancer stage [4].
